Yana G. Najjar, Caroline Robert, Nikhil I. Khushalani, Michael K.K. Wong, Tawnya Lynn Bowles, Paolo Antonio Ascierto, Georgina V. Long, Dirk Schadendorf, Allison Betof, Gregory A. Daniels, Gino Kim In, Frances A. Collichio, Ardy Davarifar, Yvonne M. Saenger, Suthee Rapisuwon, Ryan Michael Weight, Giuseppe Gullo, Marcus Viana, Mark Navarro, Omid Hamid. "A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps9597